Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment—real world comparative effectiveness from German claims data
Anti-TNF agents were most frequently used in first-line advanced therapy; however, vedolizumab appeared to be a preferred choice in terms of persistence and cost measures over three years from the start of treatment.
Authors
- Juliane Sünwoldt
- Stefan Kaiser (ORCID: https://orcid.org/0000-0002-3013-2034)
- Christina Dünweber
- Ines Weinhold (ORCID: https://orcid.org/0000-0002-7646-451X)
- Niels Teich (ORCID: https://orcid.org/0000-0002-8101-4521)
- Robert Kudernatsch
- Julia Borchert
- Axel Dignaß
Institutions
- Praxis für Humangenetik (DE)
- Takeda (Germany) (DE)
- Agaplesion Markus Hospital (DE)
- IGES Institut (DE)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1186/s12876-025-04022-7
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00